Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHE885 (durcabtagene autoleucel) in relapsed/refractory multiple myeloma
NCT05172596Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2022
- Primary completion
- May 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of durcabtagene autoleucel in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Overall Response Rate at 24 months. Started Mar 2022; status: terminated.
02
Drugs
durcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05172596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172596.